29th July 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

Zenara Pharma plans to release generic Paxlovid soon

The generic version of Paxlovid, an anti-viral medication made by Hyderabad-based Zenara Pharma, has been approved for manufacture and sale by India’s drug authority for patients with mild to moderate Covid-19 symptoms.

DoP requests industry to submit information about vaccine and biopharma raw material production capacities

Department of Pharmaceuticals (DoP) is compiling information on local producers of vaccines and biopharmaceuticals raw materials in an effort to improve the nation’s capacity for vaccine manufacturing and examine raw material availability.

GSK assist in preparing 12 European countries for an influenza pandemic

GSK committed to offer its pandemic influenza vaccine Adjupanrix to countries through a framework contract negotiated with the European Commission’s Health Emergency Preparedness and Response Authority (HERA) and supply of 85 million doses of the vaccine.

Biocon net increases by 55% in the first quarter to Rs. 167 crore

In the first quarter of 2022, which concluded in June, Biocon Limited, in comparison to the same time previous year, its consolidated revenues climbed by 21.5% to Rs. 2,140 crore from Rs. 1,761 crore.

Jharkhand govt reserves 30% of all medicine purchases for local companies in an effort to draw investors

Govt of Jharkhand has created a State Drug Procurement Policy (SDPP) that reserves 30% of the total drugs purchased by the government for local manufacturers, following the model of the central government’s flagship Make in India programme.

Sun Pharma's Q1 margins projected to be impacted by higher input costs

Sun Pharmaceutical Industries Ltd., a leading pharmaceutical company, is anticipated to report strong annual revenues in the April-June quarter (Q1FY23), up from Rs 9,719 crores the previous year to Rs 10,383 crores.

Belimumab for lupus nephritis in pediatric patients approved by FDA

Belimumab has been given FDA approval to treat children with active lupus nephritis who are simultaneously getting conventional medication. GlaxoSmithKline is responsible for both the drug’s production and marketing.

Update profile

Please update your profile to keep using the website

Start chat
Need Help?
PharmaState Academy
Hello, how can we help you?